NKGEN BIOTECH
NKGen Biotech, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK Natural Killer (NK) cell therapeutics. Leveraging proprietary cell expansion and activation technologies along with cutting-edge cell manufacturing expertise, NKGen Biotech has the ability to infinitely expand natural killer cells while significantly enhancing cytotoxicity.
NKGEN BIOTECH
Industry:
Biotechnology Life Science
Founded:
2017-01-01
Address:
Santa Ana, California, United States
Country:
United States
Website Url:
http://www.nkgenbiotech.com
Total Employee:
51+
Status:
Active
Contact:
949.396.6830
Email Addresses:
[email protected]
Total Funding:
11 M USD
Technology used in webpage:
SPF Nginx Microsoft Exchange Online Amazon Office 365 Mail Microsoft Azure DNS Amazon Route 53 Amazon CloudFront Browse Happy Google No Translate
Similar Organizations
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Gaingels
Gaingels investment in Seed Round - NKGen Biotech
Official Site Inspections
http://www.nkgenbiotech.com Semrush global rank: 3.78 M Semrush visits lastest month: 3.54 K
- Host name: chir118.websitehostserver.net
- IP address: 108.163.222.234
- Location: Chicago United States
- Latitude: 41.8777
- Longitude: -87.6376
- Metro Code: 602
- Timezone: America/Chicago
- Postal: 60604
More informations about "NKGen Biotech"
Maximizing Immune Integrity | NKGen Biotech
Interested in clinical trials evaluating the potential benefits of our SNK cell therapy?See details»
About Us | NKGen Biotech
NKGen Biotech is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies to treat neurodegenerative and …See details»
Investor Relation | NKGen Biotech
Oct 29, 2024 · NKGen Biotech’s mission is to improve patient outcomes in neurodegenerative disease and cancer by developing safe and effective cellular therapies that leverage the power of a patient’s immune system. NKGen’s …See details»
NKGen Biotech, Inc. | LinkedIn
NKGen Biotech is a clinical-stage biotechnology company harnessing the power of the body's immune system through the development and commercialization of innovative autologous, allogeneic and...See details»
NKGen Biotech - Crunchbase Company Profile & Funding
NKGen Biotech, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK Natural Killer (NK) cell …See details»
NKGen Biotech, Inc. (NKGN) Company Profile & Facts - Yahoo …
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell …See details»
NKGen Biotech, Inc. to Become Publicly Traded Company via …
Apr 15, 2023 · Using cell expansion and activation technology and cell therapy manufacturing expertise, NKGen believes it can ultimately expand natural killer cells at commercial scale …See details»
NKGen Biotech Announces Upcoming Presentation at the 16th …
Oct 15, 2024 · NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is …See details»
NKGen Biotech Announces Formation of Scientific Advisory
Mar 8, 2023 · The newly formed SAB will provide strategic, scientific, and clinical guidance as the Company progresses its pipeline of innovative natural killer cell therapies targeting …See details»
NKGen Biotech Company Profile 2024: Stock …
NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can …See details»
NKGen Biotech Announces Collaboration with the Parkinson’s …
Nov 4, 2022 · NKGen Biotech, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK …See details»
NKGen Biotech to Present New Positive SNK01 Clinical Trial
Jul 18, 2024 · NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK NK cell therapeutics. …See details»
NKGen Biotech Presents Updated NK Cell Therapy Data for
Apr 25, 2024 · NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK NK cell therapeutics. …See details»
NKGen Biotech Presents Phase 1/2a Troculeucel Data in …
Oct 29, 2024 · NKGen is developing troculeucel for the treatment of neurodegenerative disorders and a broad range of cancers. Troculeucel is the International Nonproprietary Name (“INN”) for …See details»
NKGen Biotech - Overview, News & Similar companies - ZoomInfo
May 16, 2024 · View NKGen Biotech (www.nkgenbiotech.com) location in California, United States , revenue, industry and description. Find related and similar companies as well as …See details»
NKGen Biotech to Present New Positive SNK01 Clinical Trial …
Jul 18, 2024 · NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK NK cell therapeutics. …See details»
NKGen Biotech Presents Updated Phase 1 Data on SNK02
Jun 12, 2024 · NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK NK cell therapeutics. …See details»
NKGen Biotech Announces Upcoming Presentation at the 16th …
Oct 15, 2024 · NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is …See details»
NKGen Biotech Presents Updated NK Cell Therapy Data for ...
Apr 25, 2024 · NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK NK cell therapeutics. …See details»
NKGen Biotech Presents Phase 1/2a Troculeucel Data in …
Oct 29, 2024 · Newly analyzed biomarker data from the initial dose-escalation Phase 1 AD trial found that troculeucel reduces GFAP, NfL, p-tau181, GDF-15, and LTBP2 levels, which are …See details»